POSIFLEX-TECHNOLOGY
10.12.2020 02:02:15 CET | Business Wire | Press release
Posiflex Technology, Inc. , a global leader in Point of Sale (POS), self-service kiosks, and embedded computing technologies. Posiflex has been focused on product applications of retail market trends and endeavors to improve users’ operational efficiency with cutting edge technology since its foundation in 1984. Posiflex is honored to receive the Taiwan Excellence Award 2021 for its innovative all-in-one Android POS, HS-3314A .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005001/en/
The Ministry of Economic Affairs Taiwan established the Taiwan Excellence Awards in 1993. Eligible candidates are subjected to cover four major aspects of “R&D”, “Design”, “Quality” and “Marketing” to identify outstanding products that offer “Innovative Value” while being “made in Taiwan”. Products that have been selected for the Taiwan Excellence Awards would serve as examples of the domestic industries and be promoted by the government internationally to shape the creative image for Taiwanese businesses.
The HS-3314A series is a 14” Android 9.0 PCAP touch POS system with a built-in printer and designed with the high-performance Rockchip RK3399 platform and various peripherals. Built with unique innovation and a compact body, HS-3314A is equipped with a high-speed, detachable thermal receipt printer. Its innovative screwless and modular design not only makes installation simple and maintenance easy but also allows for a variety of peripherals including a secondary display, MSR, fingerprint sensor, and barcode scanner. The whole system greatly improves retailer operation and work efficiency with space-saving design and reduced downtime.
Not only has Posiflex been building the best POS systems for the retail industry, but it is also in sync with the rapid rise of self-service technology. As the world has been deeply affected by the COVID-19 outbreak, it has unleashed a demand for safety-conscious products such as self-service kiosks. Posiflex introduces the new Mercury EK Series to its sophisticated self-service solutions to help operators succeed with the rising need for the self-service kiosk. Built to be compact and functional, the Mercury EK Series is available in 15” PCAP touch screen in landscape mode while 15.6” & 21.5” touch screens are available in both landscape and portrait mode. Designed with flexibility in mind, the Mercury EK Series can deploy as either countertop or floor-standing as well as customizable with peripherals including NFC/RFID reader, fingerprint sensor, 2D scanner, status indicator, and an EMV payment device. The versatility of the Mercury EK Series allows retailers to customize as their businesses need. They are also engineered for single-user assembly and ease of maintenance, thus reducing costs of deployment and service. With all the flexibility and user-friendly features, the Mercury EK Series can serve as an extension of employees, handling mundane tasks while allowing employees to focus on providing better customer service, therefore creating more demand and business for retailers.
With the award-winning all-in-one POS HS-3314A and the small-footprint kiosk Mercury EK Series, Posiflex provides POS/Kiosk solutions with variety and quality for the retail industry to meet customers’ various demands as well as create exceptional consumer experiences.
About Posiflex Group:
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell , further expanding into self-service and embedded PC offerings. The global Posiflex Group is in place to provide world-class B2B Serviced IoT solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom